11 research outputs found
Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment
Interferon alfa (IFN-a) is the primary treatment for
chronic hepatitis B. The standard duration of IFN-a therapy
is considered 16 weeks; however, the optimal treatment
length is still poorly defined. We evaluated the efficacy and
acceptability of prolonged IFN-a treatment in patients with
chronic hepatitis B. To investigate whether treatment prolongation
could enhance the rate of hepatitis B e antigen
(HBeAg) seroconversion, we conducted a prospective, controlled,
multicenter trial in wh
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
10.1016/j.jhep.2008.12.019Journal of Hepatology51111-20JOHE
A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals
Aims—To use laboratory data and liver biopsies, prospectively obtained from hepatitis B surface antigen (HBsAg) and anti hepatitis B e antigen (anti-HBe) positive patients, for the assessment of: (1) the relation between biopsy length/number of portal tracts and sampling error; (2) the relation between the severity of piecemeal necrosis and the new grading terminology (minimal, mild, moderate, and severe chronic hepatitis); and (3) liver pathology, which has not been studied in patients with this specific serological profile. Methods—The study group (n = 174) included 104 patients with normal aminotransferase concentrations and no cases with clinically apparent cirrhosis. The specimen length and number of portal tracts were measured at light microscopy examination. Sampling error analysis was related to the discrepancies between aminotransferase concentrations versus histological grade. Detailed histological scorings were undertaken by the reference pathologist and compared with laboratory and hepatitis B virus (HBV) DNA precore sequence data. Results—Sampling error seemed to be a constant feature, even for biopsies ≥ 20 mm, but increased dramatically in biopsies < 5 mm long and/or containing less than four portal tracts. Between 25% and 30% of biopsies, graded as "mild" or "moderate" activity showed features of moderate and severe piecemeal necrosis, respectively. Ten per cent of the patients with normal aminotransferase values had stage III–IV hepatic fibrosis, and 20% had piecemeal necrosis. Only cytoplasmic, not nuclear, core antigen expression was a strong predictor of high hepatitis B viraemia. There was no association between precore stop codon mutations, grade/stage of liver disease, and hepatitis B core antigen (HBcAg) expression. Conclusions—The specimen available for light microscopical examination should be > 5 mm long and should contain more than four portal tracts. In addition, the new grading terminology might give the clinician an inappropriately mild impression of the severity of piecemeal necrosis. Furthermore, even in the presence of normal aminotransferase concentrations, considerable liver pathology can be found in 10–20% of HBsAg and anti-HBe positive individuals; such pathology is not associated with the occurrence of precore stop codon mutations. Key Words: liver pathology • chronic hepatitis B virus infection • anti-hepatitis B antigen e positive • core antigen expression • serum hepatitis B virus DNA • hepatitis grading • sampling erro
Influence of human t-cell lymphotropic virus type 1 (HTLV-1) Infection on laboratory parameters of patients with chronic hepatitis C virus Influência da infecção pelo vírus linfotrópico humano tipo 1 (HTLV-1) em parâmetros laboratoriais de pacientes com hepatite C crônica
Hepatitis C virus (HCV) and human T-cell lymphotropic virus type 1 (HTLV-1) share routes of transmission and some individuals have dual infection. Although some studies point to a worse prognosis of hepatitis C virus in patients co-infected with HTLV-1, the interaction between these two infections is poorly understood. This study evaluated the influence of HTLV-1 infection on laboratory parameters in chronic HCV patients. Twelve HTLV-1/HCV-coinfected patients were compared to 23 patients infected only with HCV, in regard to demographic data, risk factors for viral acquisition, HCV genotype, presence of cirrhosis, T CD4+ and CD8+ cell counts and liver function tests. There was no difference in regard to age, gender, alcohol consumption, smoking habits, HCV genotype or presence of cirrhosis between the groups. Intravenous drug use was the most common risk factor among individuals co-infected with HTLV-1. These patients showed higher TCD8+ counts (p = 0.0159) and significantly lower median values of AST and ALT (p = 0.0437 and 0.0159, respectively). In conclusion, we have shown that HCV/HTLV-1 co-infected patients differs in laboratorial parameters involving both liver and immunological patterns. The meaning of these interactions in the natural history of these infections is a matter that deserves further studies.<br>O vírus da hepatite C (VHC) e vírus linfotrópico humano tipo 1 (HTLV-1) compartilham formas de transmissão e algumas pessoas apresentam coinfecção. Embora alguns estudos apontem para um pior prognóstico da infecção pelo VHC em pacientes coinfectados com HTLV-1, a interação entre estas infecções é mal compreendida. Este estudo avaliou a influência da infecção pelo HTLV-1 em parâmetros laboratoriais de pacientes com VHC. 12 coinfectados VHC/HTLV-1 foram comparados com 23 pacientes monoinfectados com VHC, no que diz respeito aos dados demográficos, fatores de risco para aquisição viral, genótipo do VHC, presença de cirrose, contagens de linfócitos T CD4+ e CD8+ e testes de função hepática. Não houve diferença em relação à idade, sexo, consumo de álcool, tabagismo, genótipo do VHC ou presença de cirrose entre os grupos. O uso de drogas injetáveis foi o fator de risco mais comum entre coinfectados. Esses pacientes apresentaram maiores contagens de linfócitos T CD8+ e valores medianos de AST e ALT significativamente mais baixos (p = 0,0437 e 0,0159, respectivamente). Em conclusão, demonstrou-se que os pacientes com VHC/HTLV-1 diferem quanto aos parâmetros hepáticos e imunológicos. O significado destas diferenças na história natural destas infecções é um assunto que merece estudos mais aprofundados